Acute infective exacerbation of chronic obstructive pulmonary diseaseBacterial conjunctivitisBacterial sinusitis, acuteCommunity acquired pneumoniaInfection of skin AND/OR subcutaneous tissue, ComplicatedInfection of skin AND/OR subcutaneous tissue, UncomplicatedInfectious disease of abdomen, ComplicatedPlague; Treatment and Prophylaxis"

Moxifloxacin is a fluoroquinolone with a broad spectrum of antimicrobial activity including G(+) and G(-) organisms, Chlamydia spp, anaerobes, and Mycobacterium tuberculosis, it inhibits bacterial DNA topoisomerases required for bacterial DNA replication, transcription, repair, and recombination.

Bioavailability approximately 90%, protein binding 50%, metabolized in liver via glucuronide and sulfate conjugation, 15~21% unchanged renal excretion, t1/2 9~16 hr.

Hypersensitivity to moxifloxacin or quinolones

C

Avoided

Nausea, diarrhea, hypertension, palpitation, QT interval prolongation, skin rash.

400 mg orally once daily

No dosage adjustment necessary.Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).

No dosage adjustment necessary; however, use with caution in this patient population secondary to the risk of QT prolongation.